Growth Metrics

RxSight (RXST) Shares Outstanding (Weighted Average) (2020 - 2026)

RxSight filings provide 6 years of Shares Outstanding (Weighted Average) readings, the most recent being $40.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 5.1% to $40.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.9 million, a 5.1% increase, with the full-year FY2025 number at $40.9 million, up 5.1% from a year prior.
  • Shares Outstanding (Weighted Average) hit $40.9 million in Q4 2025 for RxSight, roughly flat from $41.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $41.0 million in Q3 2025 to a low of $4.0 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $33.5 million (2023), compared with a mean of $29.4 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 586.3% in 2022 and later rose 5.1% in 2025.
  • RxSight's Shares Outstanding (Weighted Average) stood at $13.6 million in 2021, then soared by 103.02% to $27.7 million in 2022, then grew by 24.56% to $34.5 million in 2023, then grew by 12.81% to $38.9 million in 2024, then grew by 5.1% to $40.9 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $40.9 million (Q4 2025), $41.0 million (Q3 2025), and $40.6 million (Q2 2025) per Business Quant data.